COA ↓

Product

COA Doc

SYN-2613

99.1% Purity SYN-2613 Research Grade HPLC Verified

PT-141 (Bremelanotide)

Selective MC3R/MC4R Agonist · Research Grade

Select Strength — 10mg

$70.00

C₅₀H₆₈N₁₄O₁₀ MW: 1025.17 g/mol CAS: 189691-06-3

Out of Stock

Notify me when back in stock

For in vitro laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.

Certificate of Analysis

BATCH VERIFICATION

Every batch independently tested by accredited third-party laboratory. Full COA available on request.

Current Batch

99.1%

HPLC Purity

Lot Number SYN-2613-PT141

Test Date March 2026

Labeled 10 mg

Actual 10.02 mg

99.4%

HPLC Purity

Lot Number SYN-2512-PT141

Test Date December 2025

Labeled 10 mg

Actual 10.04 mg

Research Data

KEY FINDINGS

🧬

FDA

Approved Active Compound

Approved as Vyleesi (Palatin Technologies) for HSDD in 2019

🔬

74.7%

Responder Rate

Phase III satisfying sexual events improvement vs. 37.0% placebo

✅

99.1%

HPLC-Verified Purity

Current batch SYN-2613, third-party accredited lab

❄️

24mo

Lyophilised Shelf Life

At −20°C sealed under inert atmosphere

Mechanisms of Action

IN VITRO RESEARCH OVERVIEW

Data presented from peer-reviewed in vitro studies. All findings are laboratory observations only.

🔬 FDA Phase III Data

RECONNECT Trial — Bremelanotide for HSDD

Kingsberg et al. published the Phase III RECONNECT trial data confirming PT-141's efficacy for Hypoactive Sexual Desire Disorder. A 74.7% responder rate vs. 37.0% placebo drove FDA approval as Vyleesi in June 2019 — the first central-mechanism drug for female sexual dysfunction.

🔬 74.7% response rate — FDA-approved as Vyleesi, first CNS-acting agent for female sexual dysfunction.

PMID 31393376 — Obstet. Gynecol.

74.7 %

FDA Phase III Responder Rate (HSDD)

PT-141 (Bremelanotide) acts centrally via MC3R and MC4R in the hypothalamus — the first pro-arousal agent with a non-vascular, central nervous system mechanism validated in FDA Phase III trials for Hypoactive Sexual Desire Disorder.

Phase III RECONNECT Trial — Satisfying Sexual Events

PT-141 responders 74.7%

Placebo responders 37.0%

Source: Kingsberg SA et al., Obstet. Gynecol., 2019

Analytical Data

PURITY VERIFICATION

Purity by Method — Batch SYN-2613-PT141

Specification	Value
CAS Number	189691-06-3
Molecular Formula	C₅₀H₆₈N₁₄O₁₀
Molecular Weight	1025.17 g/mol
Purity (HPLC)	99.1%
Appearance	White lyophilised powder
Solubility	Soluble in water (1 mg/mL)
Storage	−20°C long-term / 2–8°C short-term
Shelf Life	24 months from production date
Research Grade	Yes — For In Vitro Use Only

74.7 %

Responder Rate vs. 37.0% Placebo (Phase III RECONNECT Trial)

PT-141 74.7%

Placebo 37.0%

Comparative Activity Profile

PT-141 Melanotan II

Observed Adverse Indicators

Vascular adverse effects

None

Hormone axis disruption

None

Nausea (Phase III reported)

Minimal

Flushing (MC receptor effect)

Minimal

⚠️ Theoretical Concern

Central CNS Activity — MC3R/MC4R Research Context

PT-141 acts centrally via hypothalamic MC3R/MC4R pathways. Researchers should account for CNS effects in experimental designs. Nausea was the most common adverse event in Phase III trials (reported in ~40% of subjects at therapeutic doses).

FDA-approved safety data from over 1,000 women in Phase II/III RECONNECT trials
No significant cardiovascular, hepatic, or haematological adverse findings in Phase III
Central mechanism is hormone-independent — effective across oestrogen/testosterone levels

Peer-Reviewed Literature

RESEARCH CITATIONS

Obstetrics & Gynecology

Bremelanotide for HSDD — Phase III RECONNECT Trial

2019 Kingsberg SA et al.

PMID 31393376 — View on PubMed

All citations refer to published peer-reviewed in vitro research. Data presented for scientific reference only. No claims made regarding human therapeutic use.